首页> 外文期刊>Transplantation Proceedings >Diagnostic value of serum procalcitonin in solid organ transplant recipients: A systematic review and meta-analysis
【24h】

Diagnostic value of serum procalcitonin in solid organ transplant recipients: A systematic review and meta-analysis

机译:血清降钙素原在实体器官移植受者中的诊断价值:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose To perform a systematic review and meta-analysis to define the role of procalcitonin (PCT) in identifying infectious complication in organ transplant recipients. Methods We searched EMBASE, MEDLINE, the Cochrane database, and reference lists of relevant articles, with no language restrictions, published from inception through May 2013. We selected original research that reported the diagnostic performance of PCT alone or when compared with other biomarkers to diagnose infectious complication among organ transplant recipients. We summarized test performance characteristics with the use of forest plots, hierarchical summary receiver operating characteristic curves, and bivariate random-effects models. Results We found 7 qualifying studies (studying 1226 episodes of suspected infection with 186 confirmed infectious episodes) from 4 countries. The patients were lung, kidney, liver, and heart transplant recipients. Bivariate pooled sensitivity, specificity, positive likelihood ratios, and negative likelihood ratios for identification of bacterial infections in patients after transplantation were 85% (95% confidence interval [CI], 75%-92%), 81% (95% CI, 72%-88%), 4.41 (95% CI, 2.86-6.81), and 0.18 (95% CI, 0.10-0.33), respectively. Of the 4 studies that reported the experience of liver transplant patients, the pooled sensitivity, specificity, positive likelihood ratios, and negative likelihood ratios were 90% (95% CI, 75%-97%), 85% (95% CI, 77%-91%), 6.12 (95% CI, 3.79-9.88), and 0.11 (95% CI, 0.04-0.32), respectively. There was no evidence of significant heterogeneity. Conclusion The existing literature suggests reasonable sensitivity and specificity for the PCT test in identifying infection complications among patients undergoing solid organ transplantation. Given the imperfect sensitivity and specificity of the PCT test, medical decisions should be based on both PCT test results and clinical findings.
机译:目的进行系统的回顾和荟萃分析,以定义降钙素原(PCT)在识别器官移植受者感染性并发症中的作用。方法我们搜索了从开始到2013年5月发布的EMBASE,MEDLINE,Cochrane数据库和相关文章的参考列表,没有语言限制。我们选择了仅报道PCT或与其他生物标志物进行比较来报告PCT诊断性能的原创研究,器官移植受者之间的感染性并发症。我们使用森林图,分层汇总接收器操作特征曲线和双变量随机效应模型总结了测试性能特征。结果我们发现了来自4个国家的7项合格研究(研究1226例疑似感染病例和186例确诊的传染病例)。患者是肺,肾,肝和心脏移植的受者。用于识别患者移植后细菌感染的双变量合并敏感性,特异性,阳性可能性比和阴性可能性比分别为85%(95%置信区间[CI],75%-92%),81%(95%CI,72 %-88%),4.41(95%CI,2.86-6.81)和0.18(95%CI,0.10-0.33)。在报告肝移植患者经验的4项研究中,综合敏感性,特异性,阳性似然比和阴性似然比分别为90%(95%CI,75%-97%),85%(95%CI,77) %-91%),6.12(95%CI,3.79-9.88)和0.11(95%CI,0.04-0.32)。没有证据表明存在明显的异质性。结论现有文献表明,对于PCT测试在确定实体器官移植患者的感染并发症中具有合理的敏感性和特异性。鉴于PCT测试的敏感性和特异性不完善,医学决策应基于PCT测试结果和临床发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号